Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (NCT07222345)
🩺 Plain-English Summary (8th-Grade Level)
This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated. Primary Objective: To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Feasibility will be assessed by: * Participation Rate: Number of eligible survivors approached who enroll. * Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.
Who can join: Review the eligibility criteria below.
Location: St. Jude Children's Research Hospital — Memphis, Tennessee
Age range: 10 Years to 25 Years
🧪 Interventions in This Study
- High Intensity Interval Training (HIIT) (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- St. Jude Children's Research Hospital — Memphis, Tennessee
📞 Contact the Study Coordinator
Phone: (888) 226-4343
Email: referralinfo@stjude.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hodgkin Lymphoma
- Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma — Detroit, Michigan
- Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) — Birmingham, Alabama
- PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma — Houston, Texas
- Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma — Salt Lake City, Utah
- A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) — Detroit, Michigan
- Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL — Chicago, Illinois
Explore by condition: All Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.